Sign up Australia
Tumour Trace Limited (PRIVATE-UK:TUMT)

Tumour Trace Limited (PRIVATE-UK:TUMT)


Share Price
$ 0.000
Change
0 (0.00 %)
Market Cap
$0.00 m
Proactive Investors - Run By Investors For Investors

Tumour Trace Limited

Tumour Trace is dedicated to developing innovative, patented cancer screening and diagnostic technology. Based on peer review research our in- vitro portable screening device has been validated following proof of concepts in the UK, Serbia and India. Our vision is to enable screening covering all cancers to be available to everyone, everywhere.

...

EPIC: TUMT
Market: PRIVATE-UK:TUMT
Sector: Pharmaceuticals
Website: www.tumourtrace.com

Tumour Trace Limited

www.tumourtrace.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Tumour Trace Limited


Tumour Trace Limited Snapshot

About us: The Company

About us. Tumour Trace is dedicated to developing innovative, patented cancer screening and diagnostic technology. Based on peer review research our in- vitro portable screening device has been validated following proof of concepts in the UK, Serbia and India. Our vision is to enable screening covering all cancers to be available to everyone, everywhere.

Our Unique Process

Tumour Trace

Tumour Trace uses a patented Opto-Magnetic Imaging Spectroscopy (OMIS) methodology which delivers objective results faster, at less cost and more accurately than existing methodology. Using our technology, results can be available at the point of the test or in the laboratory.

Stained or Unstained Smears

Our methodology can use either stained or unstained samples. Results are based on image processing and a statistical learning algorithm that gives results within 10 minutes. Initial studies for cervical cancer have shown an average accuracy of 95% with a sensitivity of 95.2% and a specificity of 99% with unstained inner samples.

Fast and Objective Results

Using the Opto-Magnetic (OMIS) methodology, results are available much faster with a lower percentage of false negatives than existing cancer screening methodologies. The major benefits are faster diagnosis leading to earlier treatment, which in turn can reduce costs, increase survival rates and reduce patient anxiety.

Our Passion

team

Cases of cancer are continuing to grow and the cost of screening, diagnosis and treatment are forecast to increase substantially over the next 20 years.

Our goals are simple: to enable increased levels of screening, provide objective diagnosis faster and more accurately; and provide the technology so that everyone, wherever they are in the world, can be included in a screening programme.

We have been developing the Opto-Magnetic Imaging Spectroscopy (OMIS) methodology for several years and have undertaken a number of successful validation trials in the UK, Serbia and India. We are confident that our first model will receive the CE Mark for an in-vitro diagnostics medical device early in Q2 this year for cervical, prostate, colon and oral cancers.

Much of our initial work has centred on cervical cancer, which is the 4th largest cancer in the world. Current methodology for cervical cancer using Pap/LBC methodology delivers, at best, sensitivity and specificity at 56.75% and 97.75% respectively, compared with the Tumour Trace Opto-Magnetic Imaging Spectroscopy (OMIS) method which has achieved sensitivity and specificity of 95.24% and 99% respectively.

We have also carried out preliminary tests for prostate cancer.  Current test results are, at best, 63% accurate versus the OMIS methodology which has achieved 73% accuracy.  These results have had preliminary validation with a blind study at the John van Geest Cancer Research Centre in Nottingham.

 

Lorin Johnson
Chairman

Dr Johnson is Founder and Chief Scientist of Glycyx PharmaVentures, an investment and consultancy company focused on early-stage pharma companies  having a clinical focus. Dr. Johnson is also a founder of Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) and held senior positions in Salix prior to its recent $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX).

Professor Djuro Koruga
President, Chief Scientific Officer and Technology Inventor

Professor Koruga has vast expertise from quantum computing to nanomedicine. His academic career spans decades at the forefront of nanotechnology and biomedicine. Djuro is a Gold Plaque winner from the Belgrade Association of Inventors and author of around 120 scientific papers. He is Head of The Department of Biomedical Engineering and Nanolab at the Faculty of Mechanical Engineering, University of Belgrade. As Tumour Trace’s Chair and Inventor, Professor Koruga’s invention Opto-Magnetic Imaging Spectroscopy (OMIS) brings together an application of physics and biology to create a tangible and potentially lasting change in the field of cancer screening.

Aamir Butt
Chief Executive Officer

Building a tested customer centric go-to-market strategy and executing it through focused organisational alignment is in Aamir’s DNA. With 20-years of experience of starting and selling his own businesses, and supporting over 90 other businesses, taking new products to new markets is at the heart of his expertise. Aamir has built scalable business models across several verticals including health, medtech, digital and service industries. Goal focused and results oriented, Aamir knows tools and processes deeply enough to teach, consult, coach and execute.

Stephen William Pigney
Chief Financial Office
r

Cash Management Specialist with 19 years in-depth experience, Stephen spent 18 years at Barclays’ Corporate Banking Division, moving from Senior Relationship Director into Cash Management Sales and latterly Knowledge Development.   Stephen brings his breadth of insight and acumen in delivering the finest cash management solutions, bringing extensive market and partnership understanding.

Working with some of the largest companies in the world Stephen has developed an immense know-how across all aspects of corporate cash and liquidity management; including sales, product management, advisory and training. Stephen is a published author of articles on various cash management disciplines and member of ACT Exam Board since 2002.

J Gopal Rao
Chief Operating Officer

Gopal has solid business acumen, sound people skills and an astute attention to detail. A twice graduate of the University of Cambridge, with an MBA from the Judge Business School and an MEng from the Institute for Manufacturing, Gopal won a Director’s Prize for Academic Achievement and was awarded a Sainsbury Scholarship for Social Enterprise. As a business development consultant on the Cambridge Accelerate programme, Gopal honed skills in managing multi-market platform business models and developing strategy, and at PwC he fine-tuned his knowledge of finance and EU grant funding.

Paul Darbyshire
Chief Technology Officer

Paul has designed, developed and integrated numerous leading-edge software systems and platforms driven by innovative mathematical and scientific principles for over 25 years. Paul studied for a PhD in Theoretical Physics at King’s College London where he developed and published the Darbyshire operator: a new four-dimensional matrix convolution describing various optical phenomena. After a spell in the City working for a variety of top-tier investment banks as a quantitative analyst in London, New York, Hong Kong and Singapore, Paul returned to scientific research at the University of Oxford developing cutting-edge algorithms for critical decision making in behavioral science. Prior to joining TT, he was a Senior Consultant at the Department of Life Sciences, University of Oxford, developing innovative software systems and platform technologies supporting ongoing research.

Nick Holmes
SVP Product Engineering and Design

Nick has over 20 years’ experience in taking a wide range of products through all phases of their development from initial concept, through prototyping, testing and in to production within both the UK and with manufacturers in the Far East.  With a passion for attention to detail in his designs and his particular emphasis on developing unique, creative and innovative engineering solutions to problems, Nick has several patents and design registrations to his name.

Tumour Trace Ltd
Medicity
D6 Building West,
Nottingham
NG90 6BH
UK

Email: [email protected]

Tumour Trace Limited Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use